CagriSema Food Noise: Fewer Cravings in a Trial

The new CagriSema food noise study found fewer reported cravings alongside changes in how the brain responded to food pictures. It adds evidence about appetite, but it doesn't show that every distracting food thought disappears. Food noise is a patient phrase for persistent, intrusive thoughts about food, not a diagnosis.

As of September 30, 2026, the day this article was written, Novo Nordisk had announced 52-week findings at EASD, a major diabetes research meeting. The study received a Best Abstract Award. CagriSema remains investigational: it is still being tested and has not completed regulatory review.

What the CagriSema food noise study tested

The study randomly assigned 130 adults with overweight or obesity to CagriSema or placebo, an inactive comparison treatment. There were 66 people in the CagriSema group and 64 in the placebo group. Their average age was 38, and they did not have diabetes. Participants also needed a questionnaire score indicating difficulty controlling eating.

CagriSema combines semaglutide with cagrilintide. Semaglutide copies GLP-1, a gut hormone involved in fullness; cagrilintide copies amylin, another hormone that helps signal fullness. The combination was also studied in REDEFINE 1, published in NEJM in 2025. Our cagrilintide explainer covers that ingredient's story.

In the new study, researchers measured appetite after a meal, food eaten during test meals, questionnaire answers, weight and brain responses. The main outcome was an appetite score after eating, rather than a brain-scan measure.

The EASD presentation slides reported these estimated weight changes after 52 weeks of treatment:

The announcement's 22.4% headline rounds that difference between groups. It is not the CagriSema group's weight loss on its own.

Semaglutide is one ingredient in that combination. Semaglutide by itself is a different treatment.

What this means for someone taking semaglutide

The findings support studying eating experience alongside weight. A person can notice fewer cravings, eat less during a test meal, and lose weight. Those are related outcomes, but they are different measurements.

Semaglutide alone already has human appetite data. As of September 30, 2026, the day this article was written, a 120-person trial in the American Journal of Clinical Nutrition offered useful context. Published online on June 20, 2026, it followed treatment for 60 weeks.

At week 60, the estimated reduction in calories eaten at a laboratory lunch was about 270 calories greater with semaglutide than placebo. The paper reported 269.5 calories. Yet differences in reported hunger and food preoccupation were no longer statistically clear at weeks 40 or 60.

In that trial, eating less during a test meal did not always match feeling less hungry. The paper also noted more missing follow-up data in the placebo group. A change in hunger alone cannot explain everything about treatment response.

What a brain scan can and cannot show

Functional MRI, or fMRI, estimates brain activity through changes in blood oxygen levels. It does not read thoughts directly.

Participants viewed pictures of high-calorie foods, lower-calorie foods and ordinary objects after a standardized breakfast. The brain analysis included 127 people: 65 assigned to CagriSema and 62 to placebo.

Researchers found changed response patterns in areas involved in reward, sensory processing and control of eating. That fits with participants reporting better craving control. Calling the whole brain quieter would oversimplify the finding: responses changed differently across regions.

A scan also cannot prove that a particular brain change caused a person's weight loss. Both were measured during treatment. Questionnaire results describe people's experiences; they are not a direct count of intrusive thoughts.

Several appetite and eating analyses used on-treatment data, meaning measurements collected while people were taking the medicine. They don't establish what happens after it is stopped.

Does this put CagriSema ahead of tirzepatide?

This study compared CagriSema with placebo. It did not compare the combination with tirzepatide or either ingredient alone.

That leaves an important question unanswered: how much did cagrilintide add to semaglutide's effect on cravings or brain responses? The study cannot separate the two ingredients' contributions.

Tirzepatide acts on GLP-1 and GIP, another gut hormone that helps control blood sugar. It is a different medicine with its own trial evidence. Our CagriSema versus tirzepatide comparison explains why the doses and people studied matter when comparing results.

This brain study cannot establish which medicine would suit an individual better.

Side effects belong beside the cravings results

Nearly nine in ten people taking CagriSema reported gut side effects: 89.4%, compared with 43.8% on placebo. Twelve of 66 CagriSema participants withdrew because of adverse events, or 18.2%. Two of 64 placebo participants did, or 3.1%.

Nausea and vomiting were the most common events leading to withdrawal in the CagriSema group. These figures come from the presentation's safety table, not from the announcement's headline.

That matters when interpreting the eating results. A medicine's effect on appetite sits alongside how tolerable it is. The slides reported no unexpected safety signals, but that does not mean nobody had side effects. A study this size also cannot settle uncommon risks.

The organ-fat and bone findings were separate analyses

Novo's September 30 announcement also described a sub-study within REIMAGINE 1, a diabetes trial. It used MRI, a scan that shows body tissues. It reported less abdominal, liver and pancreas fat alongside a 14.3% weight reduction at week 40.

A separate REIMAGINE 2 analysis examined bone markers, blood measures related to bone maintenance, alongside a 14.2% weight reduction at week 68. It was post hoc, meaning researchers used existing trial data to answer a question outside the main planned analysis.

These are early findings in people with type 2 diabetes. Bone-marker changes do not establish fewer fractures, and neither analysis explains the brain-scan findings by itself.

What changes for a prescription today?

The conference findings add information for a discussion about appetite and treatment goals. They do not turn a current semaglutide prescription into CagriSema.

Through Promise, semaglutide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. As of September 30, 2026, the day this article was written, the FDA's compounding explanation carried the date “Content current as of: 06/22/2026.” It explains that FDA does not review compounded preparations for safety, effectiveness or quality before they are sold.

A licensed provider may still prescribe a compounded formulation — that decision is between you and your doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.

The prescriber sets the actual dose and weighs response, side effects and medical history. This study's weight estimate is not a forecast for a compounded preparation.

What to watch next

Novo's September 30 release says it submitted CagriSema's obesity application to the US FDA in December 2025. The company expects a decision in the fourth quarter of 2026. That is an expectation, not a confirmed outcome or launch date.

For food noise, the next useful step is a full peer-reviewed report of the 52-week findings. Details about missing measurements and comparisons with the individual ingredients would help clarify the picture. So would follow-up after treatment ends: quieter cravings during treatment do not establish a permanent change.